Vonicog alfa for the treatment of von Willebrand disease

References

• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of prevalence of von Willebrand’s disease. Blood. 1987;69(2):454–459.
   PubMed Web of Science ®Google Scholar
• Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123:893–898.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost. 2011;37:425–426.
   Web of Science ®Google Scholar
• Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1 VWD). Blood. 2007;109(1):112–121.
   PubMed Web of Science ®Google Scholar
• Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983;258:2065–2067.
   PubMed Web of Science ®Google Scholar
• Sporn LA, Chavin SI, Marder VJ, et al. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76:1102–1106.
   PubMed Web of Science ®Google Scholar
• Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005;3:1710–1716.
   PubMed Web of Science ®Google Scholar
• Yee A, Kretz CA. Von Willebrand factor: form for function. Seminar Thromb Hemost. 2014;40:17–27.
   PubMed Web of Science ®Google Scholar
• Castaman G, Federici AB, Rodeghiero F, et al. Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica. 2003;88:94–108.
   PubMed Web of Science ®Google Scholar
• Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica. 2003;88:EREP02.
   PubMedGoogle Scholar
• Castaman G, Goodeve A, Eikenboom J, on behalf of the European Group on von Willebrand disease (EUVWD). Principles of care for diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667–674.
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114.
   PubMed Web of Science ®Google Scholar
• Federici AB, Budde U, Castaman G, et al. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013;39(2):191–201.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009;114(6):1158–1165.
   PubMed Web of Science ®Google Scholar
• Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and the phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM-1 VWD. Blood. 2008;111:3531–3539.
   PubMed Web of Science ®Google Scholar
• Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(3):526–534.
   PubMed Web of Science ®Google Scholar
• Castaman G, Federici AB. Type 2B von Willebrand disease: a matter of plasma plus platelet abnormality. Semin Thromb Haemost. Forthcoming 2016.
   PubMed Web of Science ®Google Scholar
• Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica. 2013;98(10):1495–1498.
   PubMed Web of Science ®Google Scholar
• Batlle J, Lopez-Fernandez MF, Fraga EL, et al. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009;20:89–100.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Franchini M. The use of plasma-derived concentrates. In: Federici AB, Lee CA, Berntorp EE, et al., editors. Von Willebrand disease. Oxford (UK): Wiley-Blackwell; 2011. p. 200–206.
   Google Scholar
• Mannucci PM, Chediak J, Hanna W, et al., the Alphanate Study Group. Treatment of von Willebrand disease with high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99:450–456.
   PubMed Web of Science ®Google Scholar
• Bello IF, Yuste VJ, Molina MQ, et al. Fanhdi, efficacy and safety in von Willebrand’s disease: prospective International study results. Haemophilia. 2007;13(Suppl 5):25–32.
   PubMed Web of Science ®Google Scholar
• Gill JC, Ewenstein BM, Thompson AR, et al., Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003;9:688–695.
   PubMed Web of Science ®Google Scholar
• Thompson AR, Gill JC, Ewenstein BM, et al., Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia. 2004;10:42–51.
   PubMed Web of Science ®Google Scholar
• Lethagen S, Kyrle PA, Castaman G, et al., the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5:1420–1430.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Tamaro G, Narchi G, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Hematol. 1987;39:467–470.
   PubMed Web of Science ®Google Scholar
• Franchini M. Surgical prophylaxis in von Willebrand’s disease: a difficult balance to manage. Blood Transfus. 2008;6(Suppl 2):33–38.
   Google Scholar
• Makris M, Colvin B, Gupta V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost. 2002;88:387–388.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88:378–379.
   PubMed Web of Science ®Google Scholar
• Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–462.
   PubMed Web of Science ®Google Scholar
• Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005;3(10):2219–2227.
   PubMed Web of Science ®Google Scholar
• Fischer BE. Recombinant von Willebrand factor: potential therapeutic use. J Thromb Thrombolysis. 1999;8(3):197–205.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32–S38.
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25:206–216.
   PubMed Web of Science ®Google Scholar
• Kragh T, Napoleone M, Fallah MA, et al. High shear dependent von Willebrand factor self-assembly fostered by platelet interaction and controlled by ADAM13. Thromb Res. 2014;133(6):1079–1087.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Kempton C, Millar C, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122(5):648–657.
   PubMed Web of Science ®Google Scholar
• Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038–2046.
   PubMed Web of Science ®Google Scholar